A Word from the CEO – March 29, 2023

A Word from the CEO – March 29, 2023

NEWS > A Word from the CEO 29 March 2023 A Word from the CEO Over the past couple of years, the U.S. Food and Drug Administration (FDA) has taken a hard-line stance against drug products approved under the accelerated approval pathway, but that have not met their...
Refusing to take no for an answer

Refusing to take no for an answer

NEWS > Refusing to take no for an answer 29 March 2023 Refusing to take no for an answer HOW EXACTIS’ COO USED HER OWN BATTLE WITH CANCER TO FIGHT FOR ALL CANCER PATIENTS Dr. Suzan McNamara knew she was too young to die. At 31, she was diagnosed with a rare disease...

Moving the needle forward

NEWS > Moving the needle forward 29 March 2023 Moving the needle forward HOW PMT COORDINATORS ARE HELPING ACCELERATE CANCER RESEARCH In May 2016, Lee-Anne Pickard, a nurse with close to 20 years of experience in cancer research, was sent an article from the...

Exactis, in top clinical trial companies based in Canada

We are pleased to have been chosen among the 39 best clinical trial companies in Canada according to the site: https://beststartup.ca/ Here is a summary of the article: This article showcases our top picks for the best Canada based Clinical Trials companies. These...

Exactis’ is pleased to announce their latest publication in Clinical and Translational Medicine entitled “Copy number and transcriptome alterations associated with metastatic lesion response to treatment in colorectal cancer”.

Since their initial description in 19481, small DNA fragments travelling in the non-cellular component of internal bodily fluids and excretions have revolutionized numerous fields in public health and preventive medicine2,3,4,5,6. Although its origins have been a...